Skip to main content

Table 2 Clinical data summary of all included studies

From: Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis

Topic Number of enrolled studies and population Study format Nationality Age Follow-up duration Treatment regimen Histology
Topic 1 25 studies (9691 treated vs. 6010 control) 3 RCTs
8 prospective cohort studies
14 retrospective cohort studies
15 Western population-based studies
10 Asian population-based studies
37 to 61 years (median) 32 months to 10 years (mean) IFN-based regimens with or without RBV, except 4 studies with a PegIFN-based regimen 10 studies exclusively assessing LC patients)
Topic 2 17 studies (9868 treated vs. 4700 controls) 1 RCT
5 prospective cohort studies
11 retrospective cohort studies
8 Western population-based studies
9 Asian population-based studies
37 to 61 years (median) 55 months to 11.5 years (median) IFN-based regimen with or without RBV, except 3 studies with a PegIFN-based regimen 3 studies exclusively assessing LC patients
Topic 3 13 studies (8671 treated vs. 2831 controls) 5 prospective cohort studies
8 retrospective cohort studies
5 Western population-based studies
8 Asian population-based studies
37 to 61 years (median) 55 months to 11.5 years (median) IFN-based regimen with or without RBV, except 2 studies with a PegIFN-based regimen 4 studies exclusively assessing LC patients
Topic 4 35 studies (14756 patients with SVR vs. 12741 patients with no SVR) 1 RCT
8 prospective cohort studies
26 retrospective cohort studies
17 Western population-based studies
17 Asian population-based studies
1 Saudi Arabia and Egypt population-based study
37 to 64 years (median) 2.1 (median) to 10 years (mean) 20 studies with PegIFN-based regimen
15 studies with IFN-based regimen
9 studies exclusively assessing LC patients
Topic 5 22 studies (12440 patients with SVR vs. 18980 patients with no SVR) 4 prospective cohort studies
18 retrospective cohort studies
12 Western population-based studies
9 Asian population-based studies
1 Saudi Arabia and Egypt population-based study
41.8 to 64 years (mean) 2.1 to 11.5 years (median) 11 studies with PegIFN-based regimen
11 studies with IFN-based regimen
3 studies exclusively assessing LC patients
Topic 6 23 studies (5148 patients with SVR vs. 10356 patients with no SVR) 7 prospective cohort studies
16 retrospective cohort studies
14 Western population-based studies
9 Asian population-based studies
41.8 to 64 (mean) 2.1 to 11.5 years (median) 12 studies with PegIFN-based regimen
11 studies with IFN-based regimen
6 studies exclusively assessing LC patients
  1. RCT randomized controlled study, IFN interferon, PegIFN pegylated interferon, RBV ribavirin, LC liver cirrhosis, SVR sustained virologic response